Pre-made Pascolizumab benchmark antibody (Whole mAb, anti-IL4 therapeutic antibody, Anti-BCGF-1/BCGF1/BSF-1/BSF1/IL-4 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-IL4 therapeutic antibody (Pre-made Pascolizumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pascolizumab is a humanized monoclonal antibody for the treatment of asthma.[1] A Phase II clinical trial in patients with symptomatic glucocorticoid naive asthma has been conducted in 21/22.[2]
| Products Name (INN Index) | Pre-Made Pascolizumab Biosimilar, Whole Mab, Anti-Il4 Antibody: Anti-BCGF-1/BCGF1/BSF-1/BSF1/IL-4 therapeutic antibody |
|---|---|
| INN Name | pascolizumab |
| Target | IL4 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – kappa |
| VD LC | IgG1 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Centocor?Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IL4 |
| Package |
